Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 01:00 save search
Global CAR-T Cell Therapy Market Report 2023: Switchable CARs, Suicide Genes & Transient Transfection to Reshape Sector Moving Forward
Published: 2023-01-06 (Crawled : 01:00) - prnewswire.com
ACLX | $52.82 -2.98% -3.12% 310K
|
|
| O: 0.95%
H: 2.51%
C: -0.77%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 3.99%
H: 19.78%
C: 17.57%
APDN | $4.776 -17.66% -2298.68% 1.2M
|
Commercial Services
|
| O: -3.03%
H: 6.25%
C: 3.12%
ANIX | $3.18 3.58% 0.97% 790
|
Health Technology
|
| O: 2.43%
H: 1.9%
C: -2.85%
global report car-t therapy market
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
Published: 2023-01-05 (Crawled : 01:00) - prnewswire.com
GSK | News | $40.86 -0.92% 0.91% 11K
|
Health Technology
|
| O: -1.28%
H: 0.35%
C: -0.29%
license agreement
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
Published: 2022-12-13 (Crawled : 01:00) - globenewswire.com
MOLN | $3.61 -6.23% -3.54% 210
|
Professional, Scientific, and T...
|
| O: 1.94%
H: 1.17%
C: 1.17%
mp0533 treatment preclinical aml t-cell molecular
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy
Published: 2022-09-13 (Crawled : 01:00) - biospace.com/
RGBP | $0.74 5.71% 5.69% 8.6K
|
Manufacturing
|
| O: 4.05%
H: 15.58%
C: 10.39%
car-t therapy
Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
Published: 2022-06-27 (Crawled : 01:00) - prnewswire.com
KPTI | $1.09 0.91% 8
|
Health Technology
|
| O: -0.58%
H: 2.33%
C: -2.52%
collaboration trial
Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022
Published: 2022-06-13 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -3.12%
H: 0.0%
C: 0.0%
INCY | $51.74 0.17% 0.14% 2
|
Health Technology
|
| O: -3.69%
H: 0.0%
C: 0.0%
car-t therapy
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Published: 2022-03-02 (Crawled : 01:00) - prnewswire.com
KPTI | $1.09 0.91% 8
|
Health Technology
|
| O: -28.03%
H: 1.74%
C: -16.2%
xpovio treatment approval cel t-cell
Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345
Published: 2022-02-21 (Crawled : 01:00) - prnewswire.com
INCY | $51.74 0.17% 0.14% 2
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
| Email alert
Add to watchlist
ibi345 car-t cel t-cell
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $51.74 0.17% 0.14% 2
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $51.74 0.17% 0.14% 2
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor
Published: 2021-11-16 (Crawled : 01:00) - poseida.com
PSTX | $2.07 -4.17% -4.6% 460K
|
Health Technology
|
| O: -1.39%
H: 0.0%
C: 0.0%
stem cell potential therapy car-t t-cell
Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control
Published: 2021-11-16 (Crawled : 01:00) - poseida.com
PSTX | $2.07 -4.17% -4.6% 460K
|
Health Technology
|
| O: -1.39%
H: 0.0%
C: 0.0%
therapy car-t t-cell
Poseida’s CAR-T Cell Therapy for Prostate Cancer Shows Promising Durable Response in Phase 1
Published: 2021-09-02 (Crawled : 01:00) - poseida.com
PSTX | $2.07 -4.17% -4.6% 460K
|
Health Technology
|
| O: 3.27%
H: 0.0%
C: -4.98%
prostate cancer phase 1 therapy car-t cancer phase 2 phase 3 response t-cell
ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas
Published: 2021-05-05 (Crawled : 01:00) - biospace.com/
ADCT | $4.78 -3.82% 2.3% 19
|
Health Technology
|
| O: -0.67%
H: 2.95%
C: -1.79%
cancer t-cell
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.